Skip to main content
Premium Trial:

Request an Annual Quote

AbCellera, Novartis Partner on Antibody Drug Discovery

NEW YORK (GenomeWeb) — AbCellera said today that it has partnered with Novartis to discover antibody-based drug candidates from natural immune responses.

Under the terms of the multiyear deal, British Columbia-based AbCellera will apply its antibody discovery platform — which combines a variety of technologies including single-cell screening, next-generation sequencing, and bioinformatics — to up to 10 targets selected by Novartis.

In exchange, the Swiss drugmaker will provide AbCellera with technology access payments, research funding, downstream milestone payments, and royalties on net product sales. Other terms were not disclosed.

"This partnership with Novartis marks an important evolution of our partnering strategy, expanding from target-based collaborations to deal structures that encourage long-term relationships and provide extended technology access to select partners," AbCellera President and CEO Carl Hansen said in a statement.

AbCellera said that it has formed over 30 antibody discovery alliances, including seven with pharmaceutical and biotech firms. In August, the company and the University of British Columbia received a C$6.5 million (US$4.9 million) grant from Genome Canada and others to develop new antibody-based therapeutics for the treatment of fibrosis-associated with Duchenne muscular dystrophy.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.